Antibody-Drug Conjugate Shows Promise in Sarcoma Trial

European Organisation for Research and Treatment of Cancer

Barcelona, Spain: An antibody-drug conjugate, a type of drug that targets and enters cancer cells like a Trojan Horse, has shown promising early results across diverse types of soft tissue sarcoma in a phase I trial. The findings are presented today (Thursday) at the 38th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

Soft tissue sarcomas develop in the body's connective tissues, such as fat, muscle, blood vessels and nerves. There are more than 100 different subtypes of sarcoma, and they can affect people of any age. If the disease spreads to other parts of the body, the outcome for patients is extremely poor, with fewer than one in five patients alive five years after diagnosis. Current treatment options are very limited and there is a clear and urgent need for better treatments.

The early trial results were presented by Patrick Schöffski, Head of the Department of General Medical Oncology at the University Hospitals Leuven and Professor in the Department of Oncology at KU Leuven, Belgium. He said: "Antibody-drug conjugates, or ADCs, have changed the treatment of several common malignancies, such as breast cancer, but none have been approved for soft tissue sarcomas. In this trial we are working with an ADC called ADCE-D01 that targets a protein called uPARAP [2].

"Our research has shown that this protein is found at high levels in the majority of sarcoma subtypes. This raises the possibility of a single targeted treatment helping patients with many different forms of this devastating disease. In this trial we are beginning to study how ADCE-D01 works in patients."

The trial includes patients being treated at seven specialist sarcoma centres in Europe and the USA [3]. Patients were aged between 21 and 83, and had one of 17 different soft tissue sarcoma subtypes, including leiomyosarcoma, synovial sarcoma, angiosarcoma and rhabdomyosarcoma. They had already received standard sarcoma treatments such as chemotherapy or targeted agents.

The first 18 patients to join the trial received ADCE-D01 once a week at a dose of 0.5 to 3.4 milligrams per kilogram of body weight (mg/kg). After clinical researchers analysed how the drug behaved in the body, the next 29 patients on the trial were given ADCE-D01 every two weeks at doses of 3.4 to 5.5 mg/kg. All patients receiving more than 3.4 mg/kg were also given G-CSF (granulocyte colony-stimulating factor), which helps the bone marrow make white blood cells, to help prevent possible side-effects of ADCE-D01. The maximum tolerated dose on the every-two-weeks schedule has not yet been reached, so testing of higher doses continues.

Of the 27 patients on the every-two-weeks schedule whose response could be assessed, eight (30%) had partial responses (where the cancer shrinks by at least 30%). Five of these responses had been confirmed on a follow-up scan and three were awaiting confirmation at the time of analysis. In addition, 85% of patients who could be evaluated had 'disease control', meaning that the cancer had either shrunk or stopped growing.

The most common treatment-related side effects were nausea, infusion-related reactions, tiredness, hair loss and neutropenia (low numbers of white blood cells called neutrophils). Treating patients with G-CSF reduced the risk of severe neutropenia. Across all doses tested on the every-two-weeks schedule, only 10% of patients required a dose reduction due to side effects, and no patients discontinued treatment due to side effects.

Professor Schöffski said: "We used data on how the drug behaves in the body to move from weekly to every-two-weeks dosing and showed that prophylactic G-CSF markedly reduced the most important side effect, severe neutropenia, while allowing higher doses to be tested. In general, the drug was well tolerated, with no interstitial lung disease, febrile neutropenia or stomatitis, and mostly low-grade gastrointestinal side effects.

"Even though this is a phase I dose-finding study with a rather small number of patients and a median follow-up of 3.4 months, the initial number of responding patients is promising.

"Comparisons between different studies must be made with caution, but for context, the therapies currently available at this stage of the disease shrink tumours in around one in ten patients or fewer. Therefore, these early results are very encouraging. Responses were seen across several soft tissue sarcoma subtypes, consistent with our lab research showing that uPARAP is present across many sarcomas."

ADCE-D01 has received Fast Track designation and Orphan Drug designation from the U.S. Food and Drug Administration for soft tissue sarcoma.

Professor Ryan B. Corcoran is AACR Co-chair of the ENA Symposium, based at Harvard Medical School, USA, and was not involved in the research. He said: "These early results from a phase I trial provide the first clinical evidence that uPARAP can be targeted with an antibody-drug conjugate in sarcoma. If these findings are confirmed in larger studies, ADCE-D01 could become a new treatment option for patients with advanced soft tissue sarcoma, who currently have few effective choices once standard chemotherapy stops working. It is encouraging that responses were seen across different subtypes and that side-effects were manageable.

"An effective and well tolerated treatment for multiple sarcoma subtypes would open new opportunities to improve the outcomes for sarcoma patients and potentially replicate the therapeutic advancements we have seen in other types of cancer, for example breast, lung or pancreatic cancer."

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.